Evidence map›Paper›PMID 41117837›Full record

Observational studyJournal of neurology2025

Whole brain volume loss is associated with a short-term disability progression in relapse-activity free multiple sclerosis.

Roland Opfer, Lothar Spies, Julia Krüger, Thomas Buddenkotte, Holger Roick, Manda Jankovic, Nicolaj Witt, Sylke Domke, Ralf Kubalek, Gerd Reifschneider and 9 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Roland Opferjung diagnostics GmbH, Hamburg, Germany.ORCID http://orcid.org/0000-0002-9911-5478
Lothar Spiesjung diagnostics GmbH, Hamburg, Germany.
Julia Krügerjung diagnostics GmbH, Hamburg, Germany.
Thomas Buddenkottejung diagnostics GmbH, Hamburg, Germany.
Holger RoickE/M/S/A, Singen, Germany.
Manda JankovicMS-Spezialambulanz, Sauerlandklinik Hachen, Sundern, Germany.
Nicolaj WittNeurologische Praxis Am Israelitischen Krankenhaus, Hamburg, Germany.
Sylke DomkeNeurologische Praxis Chemnitz-Rabenstein, Chemnitz, Germany.
Ralf KubalekNeuropraxis München Süd, Unterhaching, Germany.
Gerd ReifschneiderNeuro Centrum Odenwald, Erbach, Germany.
Jürgen KunzNeurozentrum Ravensburg, Ravensburg, Germany.
Ilias NastosMS Zentrum, Bochum, Germany.
Felicita HeidlerÖkumenisches Hainich Klinikum gGmbH, Mühlhausen, Germany.
George TrendelenburgÖkumenisches Hainich Klinikum gGmbH, Mühlhausen, Germany.
Andreas StockertFacharztpraxis Für Neurologie Und Psychiatrie, Pforzheim, Germany.
Deborah K ErhartDepartment of Neurology, University Hospital Ulm, Ulm, Germany.
Hayrettin TumaniDepartment of Neurology, University Hospital Ulm, Ulm, Germany.
Hagen H KitzlerInstitute of Diagnostic and Interventional Neuroradiology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany.
Tjalf ZiemssenMS Center, Center of Clinical Neuroscience, Neurological Clinic, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany. Tjalf.Ziemssen@ukdd.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundReliable biomarkers for disability progression independent of relapse activity (PIRA) in multiple sclerosis (MS) applicable in routine patient care are urgently needed. This study reports results from an ongoing multicenter, prospective, observational study with the primary objective of investigating the association of change in brain MRI biomarkers and PIRA.

methodsIn total 453 active relapsing remitting patients from 19 sites with baseline (BL) and one-year follow-up (FU) visits were included. At each visit, medication, relapse activity, and EDSS were recorded. MRI included 3D-T1 and 2D/3D-FLAIR. BL and FU scans enabled extraction of new/enlarged T2-lesions and brain volume loss (BVL) (annualized). Correlations and logistic regression assessed associations between EDSS progression and BVL/year.

resultsAt BL an EDSS (25%/50%/75%) of 1.5/2.0/2.5 and a time since first MS diagnosis of 2.1/5.7/11.4 years were observed. Change (FU-BL): ΔEDSS was 0.0/0.0/0.0, BVL/year was

conclusionsBVL over one year was significantly associated with EDSS progression in the absence of relapses or new lesions, confirming its value as a short-term risk marker for disability progression in MS.

Indexed as

BrainDisease ProgressionMultiple Sclerosis, Relapsing-RemittingAdultDisability EvaluationFemaleFollow-Up StudiesHumansMagnetic Resonance ImagingMaleMiddle AgedProspective StudiesRecurrenceBrain atrophyDisability progressionMagnetic resonance imagingMultiple sclerosisWhole brain volume loss

Identifiers

PMID41117837
PMCPMC12540578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.